Literature DB >> 35462657

Outcome of 18f-Fluorodeoxyglucose Positron Emission Tomography (PET)-Directed Resections in Differentiated Thyroid Carcinoma (DTC): Experience in a Developing Country.

Chandan Kumar Jha1, Anjali Mishra1, Prasanta Kumar Pradhan2, Sanjay Gambhir2, Gaurav Agarwal1, Gyan Chand1, Amit Agarwal1, Saroj Kanta Mishra1.   

Abstract

The aim of this study was to assess the accuracy of 18F-fluorodeoxyglucose positron emission tomography (18-FDG-PET scan) in localizing the disease in differentiated thyroid carcinoma patients undergoing re-operations. This is a retrospective analysis of a prospectively maintained data (December 2007 to December 2016). The patients included had elevated serum thyroglobulin (Tg) levels and negative iodine uptake (TENIS) and planned for re-operation with one or more accessible site of metastasis detected on FDG-PET scan. Clinical details, FDG-PET/CT findings, operative findings, histology, pre-, and post-operative Tg levels were recorded. Thirty-two patients were included. The mean age of the patients was 46.8 ± 15.8 years (M:F = 1:1.6) and mean pre-operative Tg value was 247.6 ± 92.3 ng/ml. FDG-PET disclosed a total of 77 hot spots in these 32 patients, 56 of which were surgically explored and resections performed. Patient- and lesion-based positive predictive value (PPV) of FDG-PET in detecting recurrent/metastatic DTC lesions was 87.5 and 71%, respectively. Remaining cases had granulomatous or nonspecific inflammatory lesions. A total of 12.5% of recurrent DTC patients explored could achieve biochemical cure. All these had disease confined to neck. Remaining patients continued to have high serum Tg level, though it fell substantially in majority of patients. False positive scans are frequent in regions with high prevalence of inflammatory diseases. Hence, FDG-PET directed re-operations should be taken up judiciously. © Indian Association of Surgical Oncology 2020.

Entities:  

Keywords:  Radio-iodine resistance; Recurrent thyroid cancer; Thyroglobulin

Year:  2020        PMID: 35462657      PMCID: PMC8986952          DOI: 10.1007/s13193-020-01087-6

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  11 in total

1.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.

Authors:  Richard J Robbins; Qiang Wan; Ravinder K Grewal; Roland Reibke; Mithat Gonen; H William Strauss; R Michael Tuttle; William Drucker; Steven M Larson
Journal:  J Clin Endocrinol Metab       Date:  2005-11-22       Impact factor: 5.958

Review 2.  Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis.

Authors:  Rosângela Caetano; Cláudia Regina Garcia Bastos; Ione Ayala Gualandi de Oliveira; Rondineli Mendes da Silva; Clarisse Pereira Dias Drumond Fortes; Vera Lucia Edais Pepe; Lenice Gnocchi Reis; José Ueleres Braga
Journal:  Head Neck       Date:  2015-05-26       Impact factor: 3.147

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.

Authors:  Meng-Jie Dong; Zhen-Feng Liu; Kui Zhao; Ling-Xiang Ruan; Guo-Lin Wang; Shu-Ye Yang; Fang Sun; Xu-Guang Luo
Journal:  Nucl Med Commun       Date:  2009-08       Impact factor: 1.690

5.  The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.

Authors:  Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

6.  Thyroid carcinoma uptake of 18F-fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy.

Authors:  Kimberly M Creach; Brian Nussenbaum; Barry A Siegel; Perry W Grigsby
Journal:  Am J Otolaryngol       Date:  2012-10-23       Impact factor: 1.808

7.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.

Authors:  U Feine; R Lietzenmayer; J P Hanke; J Held; H Wöhrle; W Müller-Schauenburg
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

8.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

9.  Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose.

Authors:  H Joensuu; A Ahonen
Journal:  J Nucl Med       Date:  1987-05       Impact factor: 10.057

10.  F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.

Authors:  Torjan Haslerud; Katrin Brauckhoff; Lars Reisæter; Regina Küfner Lein; Achim Heinecke; Jan Erik Varhaug; Martin Biermann
Journal:  Acta Radiol       Date:  2015-07-09       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.